Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors

Cancer

Volumn 78, Issue 4, 1996, Pages 901-911

  Wexler, Leonard H ^a,c   DeLaney, Thomas F ^a,d   Tsokos, Maria ^a   Avila, Nilo ^b   Steinberg, Seth M ^a   Weaver McClure, Linda ^a   Jacobson, Joan ^a,e   Jarosinski, Paul ^b   Hijazi, Yasmine M ^a   Balis, Frank M ^a   Horowitz, Marc E ^a,f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Coll Phys Surgs of Columbia Univ ^*  (United States)

^d BOSTON MEDICAL CENTER   (United States)

^e Department of Neuropsychology   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

cyclophosphamide; doxorubicin; etoposide; Ewing's sarcoma family of tumors (Ewing's sarcoma; ifosfamide; local control; peripheral neuroepithelioma); peripheral primitive neuroectodermal tumor; prognostic factors; radiation therapy; vincristi ne

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; RAZOXANE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EWING SARCOMA; FEMALE; FEVER; FOLLOW UP; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUROECTODERM TUMOR; NEUTROPENIA; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; IFOSFAMIDE; MALE; NEUTROPENIA; PILOT PROJECTS; SARCOMA, EWING'S; SOFT TISSUE NEOPLASMS; THROMBOCYTOPENIA; VINCRISTINE;

EID: 9444220857     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960815)78:4<901::AID-CNCR30>3.0.CO;2-X     Document Type: Article

References (52)

1. Tefft M, Razek A, Perez C, Burgert EO, Gehan EA, Griffin P, et al. Local control and survival related to radiation dose and volume and to chemotherapy in non-metastatic Ewing's sarcoma of pelvic bones. Int J Radiat Oncol Biol Phys 1978;4:367-72.
2. Glaubiger DL, Makuch R, Schwarz J, Levine AS, Johnson RE. Determination of prognostic factors and their influence on therapeutic results in patients with Ewing's sarcoma. Cancer 1980;45:2213-9.
3. Pilepich MV, Vietti TJ, Nesbit ME, Tefft M, Kissane J, Burgert O, et al. Radiotherapy and combination chemotherapy in advanced Ewing's Sarcoma - Intergroup study. Cancer 1981;47:1930-6.
4. Wilkins RM, Pritchard DJ, Burgert EO Jr., Unni KK. Ewing's sarcoma of bone: experience with 140 patients. Cancer 1986;58:2551-5.
5. Jürgens H, Exner U, Gadner H, Harms D, Michaelis J, Sauer R, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone: a 6-year experience of a European cooperative trial. Cancer 1988;61:23-32.
6. Bacci G, Toni A, Avella M, Manfrini M, Sudanese A, Ciaroni D, et al. Long-term results in 144 localized Ewing's sarcoma patients treated with combined therapy. Cancer 1989;63:1477-86.
7. Hayes FA, Thompson EW, Meyer WH, Kun L, Parham D, Rao B, et al. Therapy for localized Ewing's sarcoma of bone. J Clin Oncol 1989;7:208-13.
8. Barbieri E, Emiliani E, Zini G, Mancini A, Toni A, Frezza G, et al. Combined therapy of localized Ewing's sarcoma of bone: analysis of results in 100 patients. Int J Radiat Oncol Biol Phys 1990;19:1165-70.
9. Burgert EO Jr., Nesbit ME, Garnsey LA, Gehan EA, Herrmann J, Vietti TJ, et al. Multimodal therapy for management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup Study IESS-II. J Clin Oncol 1990;8:1514-24.
10. Nesbit ME Jr., Gehan EA, Burgert EO Jr., Vietti TJ, Cangir A, Tefft M, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up study of the First Intergroup Study. J Clin Oncol 1990;8:1664-74.
11. Evans RG, Nesbit ME, Gehan EA, Garnsey LA, Burgert O Jr., Vietti TJ, et al. Multimodal therapy for the management of localized Ewing's sarcoma of pelvic and sacral bones: a report from the Second Intergroup Study. J Clin Oncol 1991;9:1173-80.
12. Evans RG. The four S's of Ewing's sarcoma. Int J Radiat Oncol Biol Phys 1991;21:1671-3.
13. Dunst J, Sauer R, Burgers JMV, Hawliczek R, Kürten R, Winkelmann W, et al. Radiation therapy as local treatment in Ewing's sarcoma: results of the Cooperative Ewing's Sarcoma Studies CESS 81 and CESS 86. Cancer 1991;67:2818-25.
14. O'Connor MI, Pritchard DJ. Ewing's sarcoma: prognostic factors, disease control, and the reemerging role of surgical treatment. Clin Orthop 1991;262:78-87.
15. Hayes FA, Thompson EI, Parvey L, Rao B, Kun L, Parham D, et al. Metastatic Ewing's sarcoma: remission induction and survival. J Clin Oncol 1987;5:1199-204.
16. Arai Y, Kun LE, Brooks MT, Fairclough DL, Fontanesi J, Meyer WH, et al. Ewing's sarcoma: local tumor control and patterns of failure following limited-volume radiation therapy. Int Radiat Oncol Biol Phys 1991;21:1501-8.
17. Göbel V, Jürgens H, Etspüler G, Kemperdick H, Jungblut RM, Stienen U, et al. Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescent. J Cancer Res Clin Oncol 1987;113:187-91.
18. Cangir A, Vietti TJ, Gehan EA, Burgert EO Jr., Thomas P, Tefft M, et al. Ewing's sarcoma metastatic at diagnosis: results and comparisons of two Intergroup Ewing's Sarcoma Studies. Cancer 1990;66:887-93.
19. Horowitz ME, Kinsella TJ, Wexler LH, Belasco J, Triche T, Tsokos M, et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol 1993;11:1911-8.
20. Miser JS, Kinsella TJ, Triche TJ, Steis R, Tsokos M, Wesley R, et al. Treatment of peripheral neuroepithelioma in children and young adults. J Clin Oncol 1987;5:1752-8.
21. Miser JS, Kinsella TJ, Triche TJ, Tsokos M, Forquer R, Wesley R, et al. Preliminary results of treatment of Ewing's sarcoma of bone in children and young adults: six months of intensive combined modality treatment without maintenance. J Clin Oncol 1988;6:484-90.
22. Magrath I, Sandlund J, Raynor A, Rosenberg S, Arasi V, Miser J. A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. Cancer Chemother Pharmacol 1986;18(Suppl 2):S25-8.
23. Miser JW, Kinsella TJ, Triche TJ, Tsokos M, Jarosinski P, Forquer R, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987;5:1191-8.
24. Horowitz ME, Delaney TF, Malawer MM, Tsokos MG. Ewing's sarcoma family of tumor: Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia: JB Lippincott Co., 1993:795-821.
25. Schmidt D, Herrmann D, Jürgens H, Harms D. Malignant peripheral neuroectodermal tumor and its necessary distinction from Ewing's sarcoma. A report from the Kiel Pediatric Tumor Registry. Cancer 1991;68:2251-9.
26. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239-53.
27. Wexler LH, Andrich MP, Venzon D, Berg SL, Weaver-McClure L, Chen CC, et al. A randomized trial of the cardioprotective agent, ICRF-187, in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996;14:362-72.
28. Wexler LH, Weaver-McClure L, Steinberg SM, Jacobson J, Jarosinski P, Avila N, et al. A randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy. J Clin Oncol 1996;14:901-10.
29. Ho PTC, Zimmerman K, Wexler LH, Blaney S, Jarosinski P, Weaver-McClure L, et al. A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. Cancer 1995;76:2557-64.
30. Goldie JH, Coldman AJ, Gudauskas GA. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 1982;66:439-49.
31. Grier H, Krailo M, Link M, Tarbell N, Fryer C, Pritchard D, et al. Improved outcome in non-metastatic Ewing's sarcoma (EWS) and PNET of bone with the addition of ifosfamide (I) and etoposide (E) to vincristine (V), Adriamycin (Ad), cyclophosphamide (C), and actinomycin (A): a Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) report, [abstract 1443]. Proc Am Soc Clin Oncol 1994;13:421.
32. Oberlin O, Habrand J-L, Zucker JM, Brunat-Mentigny M, Terrier-Lacombe M-J, Dubousset J, et al. No benefit of ifosfamide in Ewing's Sarcoma: a nonrandomized study of the French Society of Pediatric Oncology. J Clin Oncol 1992;10:1407-12.
33. Heyn R, Khan F, Ensign LG, Donaldson SD, Ruymann F, Smith MA, et al. Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III: an interim report. Med Pediatr Oncol 1994;23:99-106.
34. Skinner R, Sharkey IM, Pearson ADJ, Craft AW. Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 1993;11:173-90.
35. Kinsella TJ, Miser JS, Waller B, Venzon D, Glatstein E, Weaver-McClure L, et al. Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy. Int J Radiat Oncol Biol Phys 1991;20:389-93.
36. Bacci G, Picci P, Ruggieri P, Ferrari S, Mercuri M, Fabbri N, et al. No advantages in the addition of ifosfamide and VP-16 to the standard four-drug regimen in the maintenance phase of neoadjuvant chemotherapy of Ewing's sarcoma of bone: results of two sequential studies. J Chemother 1993;5:247-57.
37. Kushner BH, Hajdu SI, Gulati SC, Erlandson RA, Exelby PR, Lieberman PH. Extracranial primitive neuroectodermal tumors: the Memorial Sloan-Kettering Cancer Center Experience. Cancer 1991;67:1825-9.
38. Whang-Peng J, Triche TJ, Knutsen T, Miser J, Kao-Shan S, Tsai S, et al. Cytogenetic characterization of selected small round cell tumors of childhood. Cancer Genet Cytogenet 1986;21:185-208.
39. Thiele CJ, McKeon C, Triche TJ, Ross RA, Reynolds CP, Israel MA. Differential protooncogene expression characterizes histopathologically indistinguishable tumors of the peripheral nervous system. J Clin Invest 1987;80:804-11.
40. Zucman J, Melot T, Desmaze C, Ghysdael J, Plougastel B, Peter M, et al. Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J 1993;12:4481-7.
41. May WA, Gishizky ML, Lessnick SL, Lunsford LB, Lewis BC, Delattre O, et al. Ewing sarcoma 11:22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLII for transformation. Proc Natl Acad Sci USA 1993;90:5752-6.
42. Malpas JS, moderator. Meeting report: First children's solid tumor group workshop on Ewing's sarcoma. 30 June to 1 July 1989. Br J Cancer 1990;62:326-30.
43. Dunst J, Jürgens H, Sauer R, Pape H, Paulussen M, Winkelmann W, et al. Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial. Int J Radiat Oncol Biol Phys 1995;32:919-30.
44. Razek A, Perez CA, Tefft M, Nesbit M, Vietti T, Burgert EO Jr, et al. Intergroup Ewing's Sarcoma Study. Local control related to radiation dose, volume, and site of primary lesion in Ewing's sarcoma. Cancer 1980;46:516-21.
45. Sailer SL, Harmon DC, Mankin HJ, Truman JT, Suit HD. Ewing's sarcoma: surgical resection as a prognostic factor. Int J Radiat Oncol Biol Phys 1988;15:43-52.
46. Scully SP, Temple HT, O'Keefe RJ, Scarborough MT, Mankin HJ, Gebhardt MC. Role of surgical resection in pelvic Ewing's sarcoma. J Clin Oncol 1995;13:2336-41.
47. Hofbauer S, Hamilton G, Theyer G, Wollmann K, Gabor F. Insulin-like growth factor-I-dependent growth and in vitro chemosensitivity of Ewing's sarcoma and peripheral primitive neuroectodermal tumour cell lines. Eur J Cancer 1993;29A:241-5.
48. Burdach S, Jürgens H, Peters C, Nürnberger W, Mauz-Körholz C, Körholz D, et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol 1993;11:1482-8.
49. Atzpodien J, Gulati SC, Shimazaki C, Bührer C, Öz S, Kwon JH, et al. Ewing's sarcoma: ex vivo sensitivity towards natural and lymphokine-activated killing. Oncology 1988;45:437-43.
50. Wexler LH, Chen C, Dilsizian V, Weaver-McClure L, Jarosinksi P, Venzon D. Use of ADR-529 (Zinecard™, ZIN) in pediatric sarcoma patients (pts) receiving a highly doxorubicin (DOX)-dose-intensive (D.I.) regimen [abstract]. J Cardiovasc Diagn Proc 1996;13:116.
51. Jones CA, Shaw PJ, Stevens MM. Use of granulocyte colony stimulating factor to reduce the toxicity of super-VAC chemotherapy in advanced solid tumors in childhood. Med Pediatr Oncol 1995;25:84-9.
52. Wexler LH, Leitman SF, Carter CS, McClure L, Yu M, Fox MC. Peripheral blood progenitor cell (PBPC) transfusions permit repetitive cycles of myeloablative chemotherapy for pediatric sarcoma patients [abstract 1460]. Proc Am Soc Clin Oncol 1995;14:454.